Software cracks, CRM leads
Software led the risk-off tape, and Salesforce (CRM) wore it as the S&P 500’s biggest decliner, logging its worst day since May 2024. In defensive sessions, high-multiple enterprise software is still the first place managers cut, and when an index heavyweight gets hit this hard, it gives the whole complex cover to sell first and ask questions later.
That tone carried into the rest of the group. Cloudflare (NET) slid in sympathy as desks treated “software” like a single crowded factor, not a set of separate fundamentals. The noise stayed familiar: de-risking ahead of near-term catalysts (including positioning around the Anthropic IPO), plus the usual grab-bag of resilience/outage chatter and AI governance anxiety. Nothing had to be decisively “wrong” in any one name. With CRM pinned to the bottom of the board, software didn’t get the benefit of the doubt.
Pre-event de-risking in tech
The same impulse spilled into other tech pockets. Palo Alto Networks (PANW) fell more than 4%, and the framing was straightforward: pre-earnings caution. Cybersecurity can still be a durable theme, but on days like this the posture shifts from “own it” to “make sure it can’t hurt the book.”
Hardware-adjacent growth had similar flow tells. Penguin Solutions (PENG) gave back early strength, losing premarket gains and fading through the session without a clean company-specific trigger. That’s usually gross exposure coming down—factor pressure flattening anything that looks like growth beta—rather than a fresh verdict on the business.
Bottom line: the calendar (earnings/IPO) plus a defensive tape raised the penalty for high-beta tech. The key change wasn’t fundamentals; it was risk budgets.
Biotech trades its own tape
Healthcare largely ignored the tech drawdown, with event-driven oncology names trading on their own clock.
- Sellas Life Sciences (SELLAS) surged to roughly triple on positive late-stage trial results for its blood cancer vaccine. That’s classic binary micro-cap price discovery: thin ownership, real data, violent re-rating.
- Greenwich LifeSciences (GLSI) pushed higher on positioning into upcoming cancer trial presentations—more setup than “the data’s in.”
Large-cap pharma stayed active through pipeline access rather than stock fireworks. Eli Lilly (LLY) was essentially flat but announced a multibillion-dollar cancer therapy partnership with Stipple Bio. The message there is consistent: oncology money is still moving, with micro-caps reacting to readouts and incumbents writing checks.
Rates, hedges, and ETF plumbing
Cross-asset, the notable shift was that bonds acted as a hedge—stocks down, bonds up—for the first time since March 2024. One day doesn’t make a regime, but if that correlation holds, it changes sizing math and can tug systematic flows.
The Federal Reserve also flagged financial stability risks tied to leveraged ETFs, citing concentrated activity like South Korean investors adding $3.8B to SOXL. The mechanics aren’t new—leveraged rebalancing can amplify moves—but explicit Fed attention makes it harder for markets to treat it as background noise.
On rates, Bank of America reiterated that short-term U.S. rates could rise further unless activity cools meaningfully. For multiple-sensitive sectors, that’s the overhang: the discount rate doesn’t need to surge to hurt—stalling is enough.
Today’s tell: software got hit because managers cut exposure, biotech held because data matters, and the macro backdrop is still asking whether rates are done tightening the screws.